There are 5 papers on LDL-C target achievement in aging research: 5 observational studies in people.
5 papers study it12 more mention it8 findings
8 new papers in 30 daysSee all 17
“the LDL-C target achievement rate was 26.4% and 29.0% with monotherapy (MT) and combination therapy (CT), respectively.”
- Humans5
Associations
7Lipid-lowering therapy
upin humans2+26% target achievement
2 studies
Lipid-lowering therapy
upin humans2+26% target achievement
Lipid-lowering therapy is associated with LDL-C target achievement in humans (High and very high cardiovascular risk) (26.4% target achievement).
“the LDL-C target achievement rate was 26.4% and 29.0% with monotherapy (MT) and combination therapy (CT), respectively.”
HumansHigh and very high cardiovascular riskmonotherapy
ESC Congress 2026 abstract
Lipid-lowering therapy is associated with LDL-C target achievement in very high-risk patients (28.48% in VH vs 21.37% overall in VH).
“Among LLT treated patients, 28.48% were on-target in VH category, 47.60% in H, 69.12% in M and 68.47% in L.”
Humansin very high-risk patients
Lipids in health and disease
Statin intolerance
downin humans1
1 study
Statin intolerance
downin humans1
Statin intolerance is associated with LDL-C target achievement in humans (High and very high cardiovascular risk) (Monotherapy, 19.1%; combination therapy, 22.1%).
“Among the high- and very-high-risk SI patients, LDL-C goal attainment rates were lower (MT, 19.1%; CT, 22.1%).”
HumansHigh and very high cardiovascular risk
ESC Congress 2026 abstract
ApoB discordance
mixedin humans1
1 study
ApoB discordance
mixedin humans1
LDL-C target achievement is associated with ApoB discordance in humans (86 patients (23.8%) had ApoB >65 mg/dL despite target LDL-C).
“However, among LDL achievers, 86 patients (23.8%) demonstrated ApoB >65 mg/dL despite target LDL-C.”
HumansACS patients achieving corrected LDL-C <55 mg/dL after PCI and triple oral lipid-lowering therapy1 monthn = 350
ESC Congress 2026 abstract
Observatory II
upin humans1
1 study
Observatory II
upin humans1
Observatory II is associated with LDL-C target achievement in humans (Observatory II compared with Observatory I, across cardiovascular risk categories) (Low risk: 55% versus 47%; moderate risk: 44% versus 36%; high risk: 33% versus 22%; very high risk: 39% versus 25%).
“These figures represent an improvement compared with Observatory I”
HumansObservatory II compared with Observatory I, across cardiovascular risk categories
ESC Congress 2026 abstract
Dyslipidemia
downin humans1−16%
1 study
Dyslipidemia
downin humans1−16%
Dyslipidemia is associated with LDL-C target achievement in humans (dyslipidemia in primary care) (15.7%).
“Only 15.7% achieved LDL-C targets.”
Humansdyslipidemia in primary caren = 2,904
Dyslipidemia in primary care patients - Treatment and control (LANTERN study) Algarve
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
Cardiovascular risk categories
downin humans1
1 study
Cardiovascular risk categories
downin humans1
Cardiovascular risk categories are associated with LDL-C target achievement in hospitalized patients (78.79% in L, 58.38% in M, 33.3% in H and 21.37% in VH).
“The percentage of on-target patients was progressively lower towards the worst categories (78.79% in L, 58.38% in M, 33.3% in H and 21.37% in VH).”
Humansin hospitalized patientsn = 13,834
Lipids in health and disease
Age
upin humans1
1 study
Age
upin humans1
Age is associated with LDL-C target achievement in humans (ASCVD patients presenting with STEMI) (43% and 49% vs 29%, p = 0.033).
“Significantly higher percentages of older/oldest ASCVD patients (43% and 49%) met LDL-C targets < 70 mg/dL compared to patients < 65 years (29%; p = 0.033)”
HumansASCVD patients presenting with STEMI
Frontiers in pharmacology